These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18987303)

  • 1. Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice.
    Kerrick WG; Kazmierczak K; Xu Y; Wang Y; Szczesna-Cordary D
    FASEB J; 2009 Mar; 23(3):855-65. PubMed ID: 18987303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients.
    Szczesna-Cordary D; Jones M; Moore JR; Watt J; Kerrick WG; Xu Y; Wang Y; Wagg C; Lopaschuk GD
    FASEB J; 2007 Dec; 21(14):3974-85. PubMed ID: 17606808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged Ca2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations.
    Wang Y; Xu Y; Kerrick WG; Wang Y; Guzman G; Diaz-Perez Z; Szczesna-Cordary D
    J Mol Biol; 2006 Aug; 361(2):286-99. PubMed ID: 16837010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice.
    Szczesna-Cordary D; Guzman G; Zhao J; Hernandez O; Wei J; Diaz-Perez Z
    J Cell Sci; 2005 Aug; 118(Pt 16):3675-83. PubMed ID: 16076902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro rescue study of a malignant familial hypertrophic cardiomyopathy phenotype by pseudo-phosphorylation of myosin regulatory light chain.
    Muthu P; Liang J; Schmidt W; Moore JR; Szczesna-Cordary D
    Arch Biochem Biophys; 2014 Jun; 552-553():29-39. PubMed ID: 24374283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts.
    Muthu P; Kazmierczak K; Jones M; Szczesna-Cordary D
    J Cell Mol Med; 2012 Apr; 16(4):911-9. PubMed ID: 21696541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.
    Yuan CC; Muthu P; Kazmierczak K; Liang J; Huang W; Irving TC; Kanashiro-Takeuchi RM; Hare JM; Szczesna-Cordary D
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4138-46. PubMed ID: 26124132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice.
    Abraham TP; Jones M; Kazmierczak K; Liang HY; Pinheiro AC; Wagg CS; Lopaschuk GD; Szczesna-Cordary D
    Cardiovasc Res; 2009 Apr; 82(1):84-92. PubMed ID: 19150977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers.
    Hernandez OM; Szczesna-Cordary D; Knollmann BC; Miller T; Bell M; Zhao J; Sirenko SG; Diaz Z; Guzman G; Xu Y; Wang Y; Kerrick WG; Potter JD
    J Biol Chem; 2005 Nov; 280(44):37183-94. PubMed ID: 16115869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice.
    Wang L; Kazmierczak K; Yuan CC; Yadav S; Kawai M; Szczesna-Cordary D
    FEBS J; 2017 Jun; 284(12):1897-1913. PubMed ID: 28467684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM.
    Yadav S; Yuan CC; Kazmierczak K; Liang J; Huang W; Takeuchi LM; Kanashiro-Takeuchi RM; Szczesna-Cordary D
    J Mol Med (Berl); 2019 Jul; 97(7):1033-1047. PubMed ID: 31101927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice.
    Kazmierczak K; Muthu P; Huang W; Jones M; Wang Y; Szczesna-Cordary D
    Biochem J; 2012 Feb; 442(1):95-103. PubMed ID: 22091967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of force-pCa relation in
    Yuan CC; Kazmierczak K; Liang J; Ma W; Irving TC; Szczesna-Cordary D
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35177471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice.
    Huang W; Liang J; Kazmierczak K; Muthu P; Duggal D; Farman GP; Sorensen L; Pozios I; Abraham TP; Moore JR; Borejdo J; Szczesna-Cordary D
    J Mol Cell Cardiol; 2014 Sep; 74():318-29. PubMed ID: 24992035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single molecule kinetics in the familial hypertrophic cardiomyopathy D166V mutant mouse heart.
    Muthu P; Mettikolla P; Calander N; Luchowski R; Gryczynski I; Gryczynski Z; Szczesna-Cordary D; Borejdo J
    J Mol Cell Cardiol; 2010 May; 48(5):989-98. PubMed ID: 19914255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity and similarity of motor function and cross-bridge kinetics in papillary muscles of transgenic mice carrying myosin regulatory light chain mutations D166V and R58Q.
    Wang L; Muthu P; Szczesna-Cordary D; Kawai M
    J Mol Cell Cardiol; 2013 Sep; 62():153-63. PubMed ID: 23727233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy.
    Kazmierczak K; Paulino EC; Huang W; Muthu P; Liang J; Yuan CC; Rojas AI; Hare JM; Szczesna-Cordary D
    Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H575-89. PubMed ID: 23748425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E22K mutation of RLC that causes familial hypertrophic cardiomyopathy in heterozygous mouse myocardium: effect on cross-bridge kinetics.
    Dumka D; Talent J; Akopova I; Guzman G; Szczesna-Cordary D; Borejdo J
    Am J Physiol Heart Circ Physiol; 2006 Nov; 291(5):H2098-106. PubMed ID: 16751284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavacamten decreases maximal force and Ca
    Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
    Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence lifetime of actin in the familial hypertrophic cardiomyopathy transgenic heart.
    Mettikolla P; Luchowski R; Gryczynski I; Gryczynski Z; Szczesna-Cordary D; Borejdo J
    Biochemistry; 2009 Feb; 48(6):1264-71. PubMed ID: 19159226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.